Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $15,477.00 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 18,425 shares of Invivyd stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $15,477.00. Following the completion of the sale, the insider directly owned 178,937 shares of the company’s stock, valued at approximately $150,307.08. This trade represents a 9.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Timothy Edward Lee also recently made the following trade(s):

• On Monday, August 17th, Timothy Edward Lee sold 22,355 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total transaction of $16,095.60.

Invivyd Price Performance

IVVD stock opened at $0.95 on Friday. The company’s 50-day moving average is $0.78 and its 200-day moving average is $1.22. The stock has a market capitalization of $280.26 million, a PE ratio of -2.88 and a beta of 0.71. Invivyd, Inc. has a 1 year low of $0.48 and a 1 year high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The firm had revenue of $14.29 million during the quarter, compared to the consensus estimate of $14.40 million. On average, analysts anticipate that Invivyd, Inc. will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Invivyd

A number of institutional investors and hedge funds have recently made changes to their positions in IVVD. Chicago Partners Investment Group LLC acquired a new position in Invivyd during the 1st quarter valued at about $25,000. Courier Capital LLC purchased a new stake in shares of Invivyd in the fourth quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Invivyd in the fourth quarter worth approximately $27,000. DRW Securities LLC bought a new position in shares of Invivyd in the fourth quarter valued at approximately $27,000. Finally, ProShare Advisors LLC bought a new position in shares of Invivyd in the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a report on Tuesday. BTIG Research reissued a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Invivyd presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.